Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

By                    

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 247-251

Spandidos Publications

Access to resources Recommend Favorite

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatinbased adjuvant chemotherapy

By                

Oncology Letters, Vol. 5, Iss. 3, 2013-01 ,pp. : 935-942

Spandidos Publications

Access to resources Recommend Favorite

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

By Shitara Kohei   Matsuo Keitaro   Muro Kei   Doi Toshihiko   Ohtsu Atsushi  

Gastric Cancer, Vol. 17, Iss. 2, 2014-04 ,pp. : 362-370

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

By Kang Eun   Im Seock-Ah   Oh Do-Youn   Han Sae-Won   Kim Jin-Soo   Choi In   Kim Jin   Kim Yu   Kim Jee   Kim Tae-You   Lee Jong   Bang Yung-Jue   Lee Keun-Wook  

Gastric Cancer, Vol. 16, Iss. 4, 2013-10 ,pp. : 581-589

Springer Publishing Company

Access to resources Recommend Favorite

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

By Takahari Daisuke   Shimada Yasuhiro   Takeshita Shigeyuki   Nishitani Hitoshi   Takashima Atsuo   Okita Natsuko   Hirashima Yoshinori   Kato Ken   Hamaguchi Tetsuya   Yamada Yasuhide   Shirao Kuniaki  

Gastric Cancer, Vol. 13, Iss. 3, 2010-08 ,pp. : 186-190

Springer Publishing Company

Access to resources Recommend Favorite